Noel Mueller
Concepts (500)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 28 | 2026 | 746 | 9.030 |
Why?
| | Microbiota | 16 | 2026 | 781 | 4.870 |
Why?
| | Cesarean Section | 14 | 2025 | 224 | 4.750 |
Why?
| | Delivery, Obstetric | 10 | 2022 | 161 | 3.780 |
Why?
| | Fatty Acids, Volatile | 8 | 2025 | 60 | 3.250 |
Why?
| | Pre-Eclampsia | 7 | 2025 | 203 | 3.030 |
Why?
| | Feces | 13 | 2026 | 506 | 2.790 |
Why?
| | Adiposity | 11 | 2024 | 537 | 2.790 |
Why?
| | Blood Pressure | 18 | 2026 | 1751 | 2.790 |
Why?
| | Trace Elements | 4 | 2021 | 51 | 2.590 |
Why?
| | Pediatric Obesity | 13 | 2025 | 627 | 2.580 |
Why?
| | Body Mass Index | 30 | 2025 | 2439 | 2.440 |
Why?
| | Menarche | 7 | 2023 | 53 | 2.410 |
Why?
| | Hypertension | 12 | 2025 | 1239 | 2.330 |
Why?
| | Milk, Human | 3 | 2026 | 171 | 2.090 |
Why?
| | Pregnancy | 42 | 2025 | 7154 | 2.070 |
Why?
| | Metals, Heavy | 3 | 2021 | 31 | 1.930 |
Why?
| | Prenatal Exposure Delayed Effects | 10 | 2024 | 667 | 1.900 |
Why?
| | Mothers | 13 | 2023 | 769 | 1.700 |
Why?
| | Metabolome | 4 | 2026 | 383 | 1.680 |
Why?
| | Vagina | 7 | 2024 | 200 | 1.630 |
Why?
| | Dietary Approaches To Stop Hypertension | 4 | 2025 | 12 | 1.600 |
Why?
| | Breast Feeding | 5 | 2026 | 444 | 1.520 |
Why?
| | Diabetes Mellitus, Type 2 | 14 | 2025 | 2590 | 1.500 |
Why?
| | Female | 111 | 2026 | 77569 | 1.490 |
Why?
| | Infant, Newborn | 25 | 2026 | 6362 | 1.460 |
Why?
| | Metformin | 5 | 2022 | 330 | 1.430 |
Why?
| | Dietary Fiber | 3 | 2023 | 58 | 1.420 |
Why?
| | Humans | 143 | 2026 | 143817 | 1.330 |
Why?
| | Fetal Blood | 4 | 2022 | 339 | 1.310 |
Why?
| | Infant | 29 | 2026 | 9886 | 1.290 |
Why?
| | Carbonated Beverages | 3 | 2015 | 16 | 1.250 |
Why?
| | Dietary Carbohydrates | 3 | 2021 | 153 | 1.210 |
Why?
| | Dietary Proteins | 2 | 2020 | 136 | 1.140 |
Why?
| | Premature Birth | 2 | 2023 | 377 | 1.130 |
Why?
| | Prospective Studies | 24 | 2026 | 7900 | 1.130 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 2098 | 1.090 |
Why?
| | Obesity | 15 | 2022 | 3073 | 1.060 |
Why?
| | Longevity | 2 | 2019 | 174 | 1.040 |
Why?
| | Diet | 15 | 2024 | 1266 | 0.990 |
Why?
| | Methylamines | 2 | 2024 | 40 | 0.980 |
Why?
| | Male | 80 | 2026 | 71568 | 0.970 |
Why?
| | Child | 37 | 2026 | 22441 | 0.960 |
Why?
| | Longitudinal Studies | 14 | 2026 | 2947 | 0.940 |
Why?
| | Non-Nutritive Sweeteners | 2 | 2015 | 7 | 0.930 |
Why?
| | Adult | 58 | 2024 | 40128 | 0.910 |
Why?
| | Health Impact Assessment | 2 | 2022 | 8 | 0.890 |
Why?
| | Diet, Sodium-Restricted | 3 | 2025 | 38 | 0.850 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2024 | 85 | 0.840 |
Why?
| | Bacteria | 6 | 2026 | 888 | 0.830 |
Why?
| | Selenium | 2 | 2021 | 49 | 0.830 |
Why?
| | Sugars | 1 | 2023 | 41 | 0.800 |
Why?
| | Insulin Resistance | 6 | 2022 | 1255 | 0.800 |
Why?
| | Anti-Bacterial Agents | 5 | 2020 | 1901 | 0.790 |
Why?
| | Infant Nutritional Physiological Phenomena | 3 | 2020 | 149 | 0.790 |
Why?
| | Manganese | 2 | 2020 | 56 | 0.790 |
Why?
| | Risk Factors | 34 | 2024 | 10623 | 0.790 |
Why?
| | Leg | 2 | 2015 | 239 | 0.770 |
Why?
| | Air Pollution | 3 | 2022 | 326 | 0.770 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 62 | 0.750 |
Why?
| | Child, Preschool | 18 | 2026 | 11631 | 0.750 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2024 | 561 | 0.730 |
Why?
| | Blood Pressure Determination | 3 | 2019 | 141 | 0.720 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 5761 | 0.720 |
Why?
| | Diet, Mediterranean | 1 | 2022 | 27 | 0.720 |
Why?
| | Body Composition | 3 | 2025 | 715 | 0.710 |
Why?
| | Chorioamnionitis | 1 | 2021 | 45 | 0.680 |
Why?
| | HTLV-I Infections | 10 | 2000 | 28 | 0.680 |
Why?
| | Birth Weight | 7 | 2024 | 524 | 0.680 |
Why?
| | Hypotension | 1 | 2022 | 127 | 0.680 |
Why?
| | Overweight | 10 | 2021 | 598 | 0.680 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 52 | 0.660 |
Why?
| | Fats, Unsaturated | 1 | 2020 | 1 | 0.640 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2020 | 24 | 0.630 |
Why?
| | Flatulence | 1 | 2019 | 2 | 0.610 |
Why?
| | Dyspepsia | 1 | 2019 | 10 | 0.610 |
Why?
| | Body Fluids | 1 | 2019 | 71 | 0.610 |
Why?
| | Weight Gain | 3 | 2018 | 559 | 0.600 |
Why?
| | Androgens | 1 | 2020 | 187 | 0.590 |
Why?
| | Pressure | 1 | 2020 | 230 | 0.580 |
Why?
| | Cohort Studies | 14 | 2023 | 5862 | 0.570 |
Why?
| | Abdominal Pain | 1 | 2020 | 145 | 0.570 |
Why?
| | Vitamin D Deficiency | 1 | 2020 | 187 | 0.560 |
Why?
| | Boston | 6 | 2021 | 93 | 0.550 |
Why?
| | Bayes Theorem | 5 | 2024 | 427 | 0.550 |
Why?
| | Vitamin D | 2 | 2023 | 402 | 0.550 |
Why?
| | Disinfectants | 1 | 2018 | 47 | 0.550 |
Why?
| | Waist Circumference | 4 | 2016 | 141 | 0.540 |
Why?
| | Estrogens | 1 | 2020 | 377 | 0.530 |
Why?
| | Middle Aged | 40 | 2025 | 35629 | 0.530 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 265 | 0.530 |
Why?
| | Skinfold Thickness | 2 | 2018 | 43 | 0.520 |
Why?
| | Biomarkers | 5 | 2024 | 4248 | 0.510 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 828 | 0.500 |
Why?
| | Age Factors | 6 | 2020 | 3288 | 0.490 |
Why?
| | Weight Loss | 5 | 2022 | 825 | 0.480 |
Why?
| | Absorptiometry, Photon | 3 | 2025 | 277 | 0.480 |
Why?
| | Puberty | 2 | 2014 | 154 | 0.470 |
Why?
| | Young Adult | 18 | 2021 | 13914 | 0.470 |
Why?
| | Asthma | 3 | 2022 | 1915 | 0.470 |
Why?
| | Gastrointestinal Tract | 2 | 2015 | 204 | 0.460 |
Why?
| | Singapore | 5 | 2013 | 26 | 0.460 |
Why?
| | Infant Welfare | 1 | 2014 | 8 | 0.440 |
Why?
| | Rural Population | 3 | 2018 | 638 | 0.440 |
Why?
| | Adolescent | 24 | 2022 | 22233 | 0.440 |
Why?
| | Brazil | 7 | 2016 | 175 | 0.430 |
Why?
| | Abdominal Fat | 1 | 2014 | 50 | 0.430 |
Why?
| | Leptin | 1 | 2016 | 244 | 0.420 |
Why?
| | Adiponectin | 1 | 2016 | 247 | 0.420 |
Why?
| | Health Status | 3 | 2023 | 821 | 0.410 |
Why?
| | Metabolic Syndrome | 4 | 2021 | 364 | 0.400 |
Why?
| | Baltimore | 2 | 2024 | 67 | 0.400 |
Why?
| | Intra-Abdominal Fat | 2 | 2024 | 101 | 0.400 |
Why?
| | Vitamins | 3 | 2024 | 177 | 0.400 |
Why?
| | Diabetes, Gestational | 2 | 2018 | 324 | 0.400 |
Why?
| | Chronic Disease | 1 | 2019 | 1826 | 0.400 |
Why?
| | Dyslipidemias | 1 | 2015 | 170 | 0.390 |
Why?
| | Glucose | 2 | 2015 | 1041 | 0.390 |
Why?
| | Feeding Behavior | 2 | 2017 | 682 | 0.390 |
Why?
| | Linear Models | 6 | 2018 | 857 | 0.390 |
Why?
| | Parity | 1 | 2013 | 110 | 0.390 |
Why?
| | Inflammation | 1 | 2024 | 2893 | 0.380 |
Why?
| | Social Class | 1 | 2015 | 270 | 0.380 |
Why?
| | Anthropometry | 1 | 2013 | 204 | 0.380 |
Why?
| | Wrist | 1 | 2013 | 60 | 0.380 |
Why?
| | Fetal Development | 1 | 2016 | 299 | 0.380 |
Why?
| | Multicenter Studies as Topic | 2 | 2024 | 394 | 0.380 |
Why?
| | Herpesvirus 4, Human | 5 | 1998 | 173 | 0.360 |
Why?
| | Time Factors | 9 | 2024 | 7068 | 0.360 |
Why?
| | Soy Foods | 1 | 2011 | 3 | 0.360 |
Why?
| | Soybean Proteins | 1 | 2011 | 14 | 0.360 |
Why?
| | Fatty Liver | 1 | 2014 | 255 | 0.360 |
Why?
| | Aged | 23 | 2025 | 25616 | 0.360 |
Why?
| | Isoflavones | 1 | 2011 | 26 | 0.360 |
Why?
| | Liver | 1 | 2020 | 1846 | 0.360 |
Why?
| | Micronutrients | 2 | 2023 | 95 | 0.360 |
Why?
| | Environmental Pollutants | 2 | 2024 | 163 | 0.350 |
Why?
| | Gestational Age | 3 | 2021 | 974 | 0.340 |
Why?
| | Butyrates | 2 | 2022 | 67 | 0.330 |
Why?
| | Obesity, Abdominal | 3 | 2016 | 46 | 0.330 |
Why?
| | Social Determinants of Health | 1 | 2015 | 294 | 0.330 |
Why?
| | Renal Dialysis | 2 | 2024 | 459 | 0.320 |
Why?
| | Bifidobacterium | 2 | 2021 | 21 | 0.320 |
Why?
| | Risk Assessment | 6 | 2024 | 3556 | 0.310 |
Why?
| | Probiotics | 2 | 2021 | 61 | 0.310 |
Why?
| | Child Health | 2 | 2023 | 154 | 0.310 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 665 | 0.300 |
Why?
| | Maternal Exposure | 2 | 2024 | 211 | 0.300 |
Why?
| | Hodgkin Disease | 4 | 1998 | 167 | 0.300 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 156 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1688 | 0.290 |
Why?
| | Protective Factors | 3 | 2019 | 102 | 0.290 |
Why?
| | Follow-Up Studies | 8 | 2018 | 5317 | 0.280 |
Why?
| | Socioeconomic Factors | 7 | 2021 | 1327 | 0.280 |
Why?
| | Denmark | 2 | 2025 | 51 | 0.280 |
Why?
| | Beverages | 2 | 2023 | 66 | 0.280 |
Why?
| | Case-Control Studies | 7 | 2023 | 3614 | 0.270 |
Why?
| | Papillomavirus Vaccines | 1 | 2012 | 298 | 0.270 |
Why?
| | Women, Working | 2 | 2017 | 12 | 0.270 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 647 | 0.270 |
Why?
| | Prevalence | 10 | 2024 | 2819 | 0.260 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 354 | 0.260 |
Why?
| | Logistic Models | 7 | 2023 | 2095 | 0.260 |
Why?
| | Quality of Life | 1 | 2019 | 3141 | 0.250 |
Why?
| | Autism Spectrum Disorder | 2 | 2024 | 431 | 0.250 |
Why?
| | Body Size | 2 | 2018 | 94 | 0.240 |
Why?
| | Sodium, Dietary | 3 | 2025 | 37 | 0.240 |
Why?
| | Incidence | 7 | 2022 | 2845 | 0.240 |
Why?
| | Infant, Low Birth Weight | 2 | 2016 | 150 | 0.230 |
Why?
| | Quebec | 1 | 2025 | 10 | 0.230 |
Why?
| | City Planning | 2 | 2022 | 3 | 0.220 |
Why?
| | Interviews as Topic | 3 | 2015 | 884 | 0.220 |
Why?
| | Blood Glucose | 5 | 2021 | 2325 | 0.220 |
Why?
| | Emergency Medical Services | 1 | 2012 | 685 | 0.220 |
Why?
| | Pregnancy Trimester, First | 2 | 2024 | 135 | 0.210 |
Why?
| | Canada | 1 | 2026 | 425 | 0.210 |
Why?
| | Infectious Mononucleosis | 2 | 1998 | 10 | 0.210 |
Why?
| | Cities | 2 | 2022 | 142 | 0.210 |
Why?
| | Ohio | 2 | 2015 | 144 | 0.210 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 115 | 0.210 |
Why?
| | Bacteroides fragilis | 1 | 2024 | 14 | 0.210 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2024 | 25 | 0.210 |
Why?
| | Diet, Vegetarian | 1 | 2024 | 10 | 0.210 |
Why?
| | Pregnancy Complications | 3 | 2024 | 590 | 0.210 |
Why?
| | Biometry | 1 | 2024 | 68 | 0.210 |
Why?
| | Folic Acid | 3 | 2024 | 196 | 0.210 |
Why?
| | Sleep | 2 | 2023 | 903 | 0.200 |
Why?
| | Kynurenine | 1 | 2024 | 113 | 0.200 |
Why?
| | Research Design | 2 | 2021 | 1121 | 0.200 |
Why?
| | Oligosaccharides | 1 | 2024 | 59 | 0.200 |
Why?
| | Homeostasis | 3 | 2016 | 638 | 0.200 |
Why?
| | Antibodies, Viral | 6 | 1991 | 684 | 0.200 |
Why?
| | Vitamin A | 1 | 2023 | 55 | 0.200 |
Why?
| | Mucus | 1 | 2024 | 78 | 0.200 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2925 | 0.200 |
Why?
| | Nutrition Assessment | 2 | 2015 | 92 | 0.200 |
Why?
| | Maternal Age | 1 | 2023 | 127 | 0.200 |
Why?
| | Metals | 1 | 2024 | 143 | 0.200 |
Why?
| | Tryptophan | 1 | 2024 | 180 | 0.190 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1402 | 0.190 |
Why?
| | Cannabidiol | 1 | 2024 | 134 | 0.190 |
Why?
| | Phthalic Acids | 1 | 2022 | 51 | 0.190 |
Why?
| | Aging | 2 | 2024 | 1968 | 0.190 |
Why?
| | District of Columbia | 3 | 2021 | 35 | 0.180 |
Why?
| | Hepatitis C | 3 | 2000 | 249 | 0.180 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 67 | 0.180 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 245 | 0.180 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.180 |
Why?
| | Dronabinol | 1 | 2024 | 247 | 0.180 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2021 | 32 | 0.180 |
Why?
| | Regression Analysis | 3 | 2012 | 1003 | 0.180 |
Why?
| | Sodium | 2 | 2021 | 198 | 0.180 |
Why?
| | Urban Health | 1 | 2022 | 95 | 0.180 |
Why?
| | HTLV-I Antibodies | 5 | 1992 | 6 | 0.180 |
Why?
| | Glycemic Index | 1 | 2021 | 27 | 0.170 |
Why?
| | Permeability | 1 | 2022 | 168 | 0.170 |
Why?
| | Cardiovascular System | 1 | 2023 | 140 | 0.170 |
Why?
| | Purines | 1 | 2022 | 188 | 0.170 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 927 | 0.170 |
Why?
| | Clostridium perfringens | 1 | 2021 | 5 | 0.170 |
Why?
| | Clostridium | 1 | 2021 | 19 | 0.170 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 127 | 0.170 |
Why?
| | Bacteroides | 1 | 2021 | 20 | 0.170 |
Why?
| | Oxides | 1 | 2021 | 51 | 0.170 |
Why?
| | Smoking | 4 | 2013 | 1556 | 0.170 |
Why?
| | Registries | 2 | 2024 | 2242 | 0.170 |
Why?
| | Growth | 1 | 2021 | 51 | 0.170 |
Why?
| | Sex Characteristics | 2 | 2016 | 786 | 0.160 |
Why?
| | Odds Ratio | 6 | 2023 | 1057 | 0.160 |
Why?
| | Glomerular Filtration Rate | 1 | 2024 | 751 | 0.160 |
Why?
| | Minority Groups | 1 | 2022 | 280 | 0.160 |
Why?
| | Uric Acid | 1 | 2021 | 166 | 0.160 |
Why?
| | Postpartum Period | 1 | 2023 | 360 | 0.160 |
Why?
| | Skin Absorption | 1 | 2019 | 13 | 0.160 |
Why?
| | Dysbiosis | 1 | 2021 | 186 | 0.160 |
Why?
| | Massachusetts | 1 | 2020 | 181 | 0.160 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 94 | 0.160 |
Why?
| | Models, Statistical | 1 | 2024 | 680 | 0.160 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 26 | 0.150 |
Why?
| | Vulnerable Populations | 1 | 2021 | 172 | 0.150 |
Why?
| | Appetite | 1 | 2020 | 71 | 0.150 |
Why?
| | Digestive System | 1 | 2019 | 28 | 0.150 |
Why?
| | Sex Factors | 4 | 2019 | 2078 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2024 | 1223 | 0.150 |
Why?
| | Mercury | 1 | 2019 | 39 | 0.150 |
Why?
| | Cholesterol, HDL | 1 | 2020 | 194 | 0.150 |
Why?
| | Cost of Illness | 1 | 2022 | 320 | 0.150 |
Why?
| | Cadmium | 1 | 2019 | 68 | 0.150 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2021 | 320 | 0.150 |
Why?
| | Venezuela | 1 | 2018 | 8 | 0.150 |
Why?
| | Lead | 1 | 2019 | 70 | 0.150 |
Why?
| | Men's Health | 1 | 2018 | 6 | 0.150 |
Why?
| | Employment | 2 | 2017 | 180 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2019 | 200 | 0.140 |
Why?
| | Age Distribution | 2 | 2018 | 395 | 0.140 |
Why?
| | United States | 8 | 2023 | 15602 | 0.140 |
Why?
| | DNA, Bacterial | 1 | 2020 | 341 | 0.140 |
Why?
| | Behavior Therapy | 1 | 2021 | 286 | 0.140 |
Why?
| | Dizziness | 1 | 2019 | 94 | 0.140 |
Why?
| | Nutritional Status | 2 | 2024 | 351 | 0.140 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 1991 | 124 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 873 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2024 | 596 | 0.140 |
Why?
| | Age of Onset | 2 | 2016 | 543 | 0.140 |
Why?
| | Cholesterol, LDL | 1 | 2020 | 347 | 0.140 |
Why?
| | Skin | 1 | 2023 | 760 | 0.140 |
Why?
| | Nutrition Surveys | 2 | 2021 | 279 | 0.130 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2018 | 83 | 0.130 |
Why?
| | Reference Values | 1 | 2019 | 806 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2021 | 315 | 0.130 |
Why?
| | Public Health | 2 | 2021 | 560 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 6004 | 0.130 |
Why?
| | Infant, Small for Gestational Age | 1 | 2018 | 108 | 0.130 |
Why?
| | Verrucomicrobia | 1 | 2016 | 5 | 0.130 |
Why?
| | Leukocytes | 1 | 2018 | 293 | 0.130 |
Why?
| | Colombia | 2 | 2016 | 42 | 0.130 |
Why?
| | Japan | 6 | 2000 | 141 | 0.130 |
Why?
| | Computational Biology | 1 | 2021 | 683 | 0.120 |
Why?
| | Confidence Intervals | 2 | 2012 | 330 | 0.120 |
Why?
| | Income | 1 | 2017 | 197 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1047 | 0.120 |
Why?
| | Developing Countries | 2 | 2017 | 313 | 0.120 |
Why?
| | Disease Progression | 1 | 2024 | 2871 | 0.120 |
Why?
| | Death | 1 | 2017 | 130 | 0.120 |
Why?
| | Aspartame | 1 | 2015 | 5 | 0.120 |
Why?
| | Preconception Care | 1 | 2016 | 50 | 0.120 |
Why?
| | Liver Neoplasms | 2 | 2000 | 774 | 0.110 |
Why?
| | Intestines | 1 | 2018 | 354 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1675 | 0.110 |
Why?
| | Phylogeny | 1 | 2020 | 1011 | 0.110 |
Why?
| | Coffee | 1 | 2015 | 15 | 0.110 |
Why?
| | Epidemiologic Methods | 2 | 2013 | 92 | 0.110 |
Why?
| | Particulate Matter | 1 | 2018 | 342 | 0.110 |
Why?
| | Nutrition Policy | 1 | 2015 | 55 | 0.110 |
Why?
| | Caffeine | 1 | 2015 | 72 | 0.110 |
Why?
| | China | 1 | 2015 | 225 | 0.110 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2015 | 104 | 0.110 |
Why?
| | Dietary Supplements | 3 | 2024 | 576 | 0.110 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 196 | 0.110 |
Why?
| | Organ Size | 1 | 2015 | 469 | 0.110 |
Why?
| | Body Weight | 1 | 2019 | 993 | 0.110 |
Why?
| | Animals | 7 | 2024 | 38140 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2024 | 11459 | 0.100 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1305 | 0.100 |
Why?
| | California | 1 | 2015 | 464 | 0.100 |
Why?
| | Immunoglobulin M | 3 | 1991 | 287 | 0.100 |
Why?
| | Physical Examination | 1 | 2015 | 235 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1508 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4211 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2015 | 1308 | 0.100 |
Why?
| | Glucose Metabolism Disorders | 1 | 2012 | 11 | 0.090 |
Why?
| | Diabetic Angiopathies | 1 | 2014 | 251 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2019 | 1377 | 0.090 |
Why?
| | Central America | 1 | 2012 | 24 | 0.090 |
Why?
| | Sarcoma, Kaposi | 2 | 1997 | 83 | 0.090 |
Why?
| | South America | 1 | 2012 | 56 | 0.090 |
Why?
| | Capsid Proteins | 2 | 1991 | 96 | 0.090 |
Why?
| | Area Under Curve | 1 | 2012 | 333 | 0.090 |
Why?
| | Abdomen | 1 | 2012 | 141 | 0.090 |
Why?
| | Brain | 1 | 2023 | 2901 | 0.080 |
Why?
| | Demography | 3 | 2017 | 289 | 0.080 |
Why?
| | Antigens, Viral | 3 | 1999 | 183 | 0.080 |
Why?
| | Immunoglobulin G | 3 | 1991 | 899 | 0.080 |
Why?
| | Cytokines | 1 | 2018 | 2093 | 0.080 |
Why?
| | ROC Curve | 1 | 2012 | 607 | 0.080 |
Why?
| | Carrier State | 3 | 1998 | 79 | 0.080 |
Why?
| | Occupations | 3 | 2017 | 50 | 0.080 |
Why?
| | Dietary Sucrose | 1 | 2010 | 50 | 0.080 |
Why?
| | Diabetes Mellitus | 2 | 2016 | 1088 | 0.070 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2012 | 275 | 0.070 |
Why?
| | Health Promotion | 1 | 2015 | 765 | 0.070 |
Why?
| | Mice | 2 | 2024 | 18421 | 0.070 |
Why?
| | Epidemiology | 1 | 2008 | 33 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2097 | 0.070 |
Why?
| | India | 2 | 2021 | 216 | 0.070 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1997 | 230 | 0.060 |
Why?
| | Smoking Cessation | 1 | 2011 | 434 | 0.060 |
Why?
| | Cytomegalovirus | 1 | 1988 | 168 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1393 | 0.060 |
Why?
| | Patient Selection | 1 | 2011 | 695 | 0.060 |
Why?
| | Testicular Neoplasms | 1 | 1988 | 112 | 0.060 |
Why?
| | Human T-lymphotropic virus 1 | 2 | 1999 | 32 | 0.060 |
Why?
| | Nucleoside-Triphosphatase | 1 | 2006 | 14 | 0.060 |
Why?
| | Flavivirus | 1 | 2006 | 19 | 0.060 |
Why?
| | RNA Helicases | 1 | 2006 | 32 | 0.060 |
Why?
| | Waist-Hip Ratio | 2 | 2016 | 37 | 0.060 |
Why?
| | Viral Nonstructural Proteins | 1 | 2006 | 67 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1807 | 0.060 |
Why?
| | Binomial Distribution | 1 | 2024 | 8 | 0.050 |
Why?
| | Spatial Analysis | 1 | 2024 | 23 | 0.050 |
Why?
| | Lipids | 2 | 2022 | 699 | 0.050 |
Why?
| | Georgia | 1 | 2024 | 86 | 0.050 |
Why?
| | Germany | 1 | 2024 | 141 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2782 | 0.050 |
Why?
| | Insulin | 3 | 2021 | 2502 | 0.050 |
Why?
| | Appointments and Schedules | 1 | 2024 | 98 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2012 | 1078 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2018 | 16755 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 594 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 169 | 0.050 |
Why?
| | Heartburn | 1 | 2021 | 12 | 0.040 |
Why?
| | Hospitalization | 2 | 2024 | 2340 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 2021 | 77 | 0.040 |
Why?
| | Maryland | 1 | 2021 | 63 | 0.040 |
Why?
| | American Heart Association | 1 | 2023 | 301 | 0.040 |
Why?
| | Hunger | 1 | 2021 | 56 | 0.040 |
Why?
| | Gout | 1 | 2021 | 35 | 0.040 |
Why?
| | Iron | 1 | 2023 | 355 | 0.040 |
Why?
| | Africa, Eastern | 1 | 2020 | 12 | 0.040 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 2 | 1991 | 17 | 0.040 |
Why?
| | Transportation | 1 | 2020 | 55 | 0.040 |
Why?
| | Capital Financing | 1 | 2020 | 7 | 0.040 |
Why?
| | Causality | 1 | 2020 | 126 | 0.040 |
Why?
| | Tuberculin | 1 | 1999 | 8 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 494 | 0.040 |
Why?
| | Hepacivirus | 2 | 1998 | 232 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 89 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2017 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 221 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2019 | 114 | 0.040 |
Why?
| | Meconium | 1 | 2018 | 7 | 0.040 |
Why?
| | Oncogene Proteins, Viral | 1 | 1998 | 22 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 1998 | 30 | 0.040 |
Why?
| | Th1 Cells | 1 | 1999 | 142 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 162 | 0.040 |
Why?
| | Diet, Western | 1 | 2019 | 85 | 0.030 |
Why?
| | Virus Latency | 1 | 1998 | 87 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2022 | 584 | 0.030 |
Why?
| | Aged, 80 and over | 5 | 1997 | 8130 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 113 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 398 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.030 |
Why?
| | Sex Distribution | 2 | 2014 | 379 | 0.030 |
Why?
| | Calcium | 1 | 2023 | 1181 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 517 | 0.030 |
Why?
| | Immunologic Memory | 1 | 1999 | 375 | 0.030 |
Why?
| | Cancer Survivors | 1 | 2021 | 309 | 0.030 |
Why?
| | Mucins | 1 | 2016 | 77 | 0.030 |
Why?
| | Deltaretrovirus Antibodies | 1 | 1996 | 1 | 0.030 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2016 | 54 | 0.030 |
Why?
| | Viral Proteins | 1 | 1998 | 365 | 0.030 |
Why?
| | Health Care Costs | 1 | 2019 | 416 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 794 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 509 | 0.030 |
Why?
| | Disease Transmission, Infectious | 1 | 1996 | 68 | 0.030 |
Why?
| | Educational Status | 1 | 2017 | 463 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2018 | 377 | 0.030 |
Why?
| | Dominican Republic | 1 | 2015 | 26 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 466 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1459 | 0.030 |
Why?
| | New York | 1 | 2015 | 125 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2019 | 592 | 0.030 |
Why?
| | RNA, Viral | 1 | 1998 | 690 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2014 | 46 | 0.030 |
Why?
| | Gene Products, tax | 2 | 1991 | 15 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2015 | 121 | 0.030 |
Why?
| | Hepatitis B | 1 | 1995 | 68 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2015 | 376 | 0.030 |
Why?
| | Poverty | 1 | 2017 | 522 | 0.030 |
Why?
| | HTLV-I Antigens | 2 | 1991 | 2 | 0.020 |
Why?
| | Communication | 1 | 2020 | 959 | 0.020 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 2 | 1991 | 12 | 0.020 |
Why?
| | Colorado | 1 | 2023 | 4578 | 0.020 |
Why?
| | HIV Seroprevalence | 1 | 1992 | 4 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1984 | 0.020 |
Why?
| | Serologic Tests | 1 | 1992 | 53 | 0.020 |
Why?
| | Forestry | 1 | 1992 | 5 | 0.020 |
Why?
| | Fisheries | 1 | 1992 | 3 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 1991 | 5 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1427 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1992 | 43 | 0.020 |
Why?
| | Homosexuality | 2 | 1992 | 17 | 0.020 |
Why?
| | Bisexuality | 2 | 1992 | 36 | 0.020 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 1991 | 20 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 370 | 0.020 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1991 | 4 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1995 | 370 | 0.020 |
Why?
| | Capsid | 1 | 1991 | 94 | 0.020 |
Why?
| | Agriculture | 1 | 1992 | 102 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3392 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 1991 | 168 | 0.020 |
Why?
| | Dysgerminoma | 1 | 1988 | 7 | 0.020 |
Why?
| | Sexual Behavior | 1 | 1992 | 490 | 0.020 |
Why?
| | Immunoglobulin A | 1 | 1989 | 218 | 0.020 |
Why?
| | Science | 1 | 2008 | 54 | 0.020 |
Why?
| | United Kingdom | 1 | 2008 | 332 | 0.020 |
Why?
| | Teratoma | 1 | 1988 | 120 | 0.020 |
Why?
| | History, 20th Century | 1 | 2008 | 327 | 0.020 |
Why?
| | Risk | 1 | 1989 | 901 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3182 | 0.010 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 2914 | 0.010 |
Why?
| | HIV-1 | 1 | 1992 | 904 | 0.010 |
Why?
| | Neoplasms | 1 | 2021 | 2902 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 392 | 0.010 |
Why?
| | Health Personnel | 1 | 1992 | 741 | 0.010 |
Why?
| | Virus Replication | 1 | 1987 | 537 | 0.010 |
Why?
| | Recombinant Proteins | 2 | 1999 | 1355 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2148 | 0.010 |
Why?
| | Transcription Factors | 1 | 1989 | 1735 | 0.010 |
Why?
| | Tritium | 1 | 1999 | 68 | 0.010 |
Why?
| | Thymidine | 1 | 1999 | 59 | 0.010 |
Why?
| | Mycobacterium bovis | 1 | 1999 | 15 | 0.010 |
Why?
| | BCG Vaccine | 1 | 1999 | 26 | 0.010 |
Why?
| | Interleukin-12 | 1 | 1999 | 121 | 0.010 |
Why?
| | Erythema | 1 | 1998 | 28 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 1999 | 125 | 0.010 |
Why?
| | Blotting, Western | 2 | 1991 | 1207 | 0.010 |
Why?
| | Interleukin-2 | 1 | 1999 | 447 | 0.010 |
Why?
| | Cell Division | 1 | 1999 | 780 | 0.010 |
Why?
| | Greece | 1 | 1997 | 8 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1999 | 791 | 0.010 |
Why?
| | Hepatitis Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1995 | 19 | 0.010 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 1995 | 16 | 0.010 |
Why?
| | Hepatitis B virus | 1 | 1995 | 31 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 1995 | 174 | 0.010 |
Why?
| | Eye Diseases | 1 | 1995 | 94 | 0.010 |
Why?
| | Life Style | 1 | 1995 | 485 | 0.010 |
Why?
| | Retroviruses, Simian | 1 | 1991 | 1 | 0.010 |
Why?
| | Genes, pX | 1 | 1991 | 2 | 0.010 |
Why?
| | Papio | 1 | 1991 | 92 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1999 | 4172 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1995 | 405 | 0.010 |
Why?
| | Mexico | 1 | 1992 | 231 | 0.010 |
Why?
| | Agglutination Tests | 1 | 1991 | 4 | 0.010 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 1990 | 6 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1991 | 167 | 0.010 |
Why?
| | DNA, Viral | 1 | 1991 | 361 | 0.000 |
Why?
| | Antibody Formation | 1 | 1991 | 294 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 64 | 0.000 |
Why?
| | Precipitin Tests | 1 | 1989 | 95 | 0.000 |
Why?
| | Lymphocytes | 1 | 1991 | 395 | 0.000 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 330 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1991 | 1057 | 0.000 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 856 | 0.000 |
Why?
| | Base Sequence | 1 | 1991 | 2186 | 0.000 |
Why?
| | Alcohol Drinking | 1 | 1995 | 831 | 0.000 |
Why?
| | Family | 1 | 1991 | 692 | 0.000 |
Why?
| | Trans-Activators | 1 | 1989 | 398 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2894 | 0.000 |
Why?
|
|
Mueller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|